Coastline Trust Co grew its holdings in Pfizer Inc. (NYSE:PFE) by 6.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,064 shares of the biopharmaceutical company’s stock after purchasing an additional 6,304 shares during the quarter. Coastline Trust Co’s holdings in Pfizer were worth $3,856,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in PFE. BlackRock Inc. lifted its position in shares of Pfizer by 0.8% during the 2nd quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock worth $13,980,372,000 after buying an additional 3,464,207 shares in the last quarter. State Street Corp raised its holdings in Pfizer by 0.3% during the 1st quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock valued at $9,551,162,000 after acquiring an additional 830,299 shares during the period. Capital World Investors lifted its position in shares of Pfizer by 19.1% during the first quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock worth $7,337,737,000 after acquiring an additional 36,092,723 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Pfizer by 1.8% in the second quarter. Bank of New York Mellon Corp now owns 57,111,863 shares of the biopharmaceutical company’s stock worth $1,867,559,000 after acquiring an additional 1,024,264 shares during the period. Finally, Sanders Capital LLC boosted its holdings in shares of Pfizer by 5.0% in the second quarter. Sanders Capital LLC now owns 28,282,011 shares of the biopharmaceutical company’s stock worth $1,046,595,000 after acquiring an additional 1,349,012 shares during the period. Institutional investors own 69.08% of the company’s stock.
Shares of NYSE PFE traded up $1.40 during trading hours on Friday, reaching $37.95. 40,790,772 shares of the stock traded hands, compared to its average volume of 28,495,957. The company’s 50-day simple moving average is $36.59 and its two-hundred day simple moving average is $36.32. The company has a market capitalization of $210.88 billion, a P/E ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $40.97. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $11.80 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same period last year, the firm posted $0.80 earnings per share. The business’s revenue was down 11.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, November 6th will be given a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 annualized dividend and a yield of 4.01%. Pfizer’s payout ratio is 51.53%.
In related news, Director Ronald E. Blaylock acquired 13,000 shares of Pfizer stock in a transaction dated Thursday, August 6th. The shares were purchased at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the purchase, the director now owns 4,000 shares of the company’s stock, valued at $154,200. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.08% of the company’s stock.
A number of brokerages recently issued reports on PFE. ValuEngine cut Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. SVB Leerink raised their price objective on shares of Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a research report on Wednesday, July 29th. Royal Bank of Canada set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Friday. Berenberg Bank initiated coverage on shares of Pfizer in a research note on Tuesday, September 29th. They issued a “hold” rating and a $38.00 target price on the stock. Finally, Mizuho restated a “buy” rating and set a $43.00 price target on shares of Pfizer in a research report on Tuesday, September 15th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $39.64.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.